JP2011524887A5 - - Google Patents

Download PDF

Info

Publication number
JP2011524887A5
JP2011524887A5 JP2011514119A JP2011514119A JP2011524887A5 JP 2011524887 A5 JP2011524887 A5 JP 2011524887A5 JP 2011514119 A JP2011514119 A JP 2011514119A JP 2011514119 A JP2011514119 A JP 2011514119A JP 2011524887 A5 JP2011524887 A5 JP 2011524887A5
Authority
JP
Japan
Prior art keywords
retroviral vector
formulation
ultrafiltration
filter
sterilization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011514119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011524887A (ja
JP5615271B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2009/001527 external-priority patent/WO2009153563A1/en
Publication of JP2011524887A publication Critical patent/JP2011524887A/ja
Publication of JP2011524887A5 publication Critical patent/JP2011524887A5/ja
Application granted granted Critical
Publication of JP5615271B2 publication Critical patent/JP5615271B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011514119A 2008-06-18 2009-06-18 ウイルス精製法 Active JP5615271B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7368508P 2008-06-18 2008-06-18
US61/073,685 2008-06-18
PCT/GB2009/001527 WO2009153563A1 (en) 2008-06-18 2009-06-18 Virus purification

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014142447A Division JP6002720B2 (ja) 2008-06-18 2014-07-10 ウイルス精製法

Publications (3)

Publication Number Publication Date
JP2011524887A JP2011524887A (ja) 2011-09-08
JP2011524887A5 true JP2011524887A5 (enExample) 2012-07-19
JP5615271B2 JP5615271B2 (ja) 2014-10-29

Family

ID=40940324

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011514119A Active JP5615271B2 (ja) 2008-06-18 2009-06-18 ウイルス精製法
JP2014142447A Expired - Fee Related JP6002720B2 (ja) 2008-06-18 2014-07-10 ウイルス精製法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014142447A Expired - Fee Related JP6002720B2 (ja) 2008-06-18 2014-07-10 ウイルス精製法

Country Status (8)

Country Link
US (1) US9169491B2 (enExample)
EP (2) EP3192874B1 (enExample)
JP (2) JP5615271B2 (enExample)
CN (2) CN102124115B (enExample)
DK (2) DK2307551T3 (enExample)
ES (2) ES2762864T3 (enExample)
PL (2) PL2307551T3 (enExample)
WO (1) WO2009153563A1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX340102B (es) * 2010-01-28 2016-06-24 The Children's Hospital Of Philadelphia * Una plataforma de fabricacion ajustable en escala, para la purificacion de vector viral y vectores virales asi purificados para el uso en terapia de genes.
WO2011148194A1 (en) 2010-05-28 2011-12-01 Oxford Biomedica (Uk) Ltd Delivery of lentiviral vectors to the brain
GB201118636D0 (en) 2011-10-28 2011-12-07 Oxford Biomedica Ltd Nucleotide sequence
EP3327119A1 (en) 2011-11-24 2018-05-30 Genethon Scalable lentiviral vector production system compatible with industrial pharmaceutical applications
DK2790737T3 (en) 2011-12-12 2019-03-18 Childrens Hospital Philadelphia COMMERCIAL LARGE SCALE LENTIVIRUS VECTOR-MANUFACTURING SYSTEM AND VECTORS MADE THEREOF
EP2802649B1 (en) 2012-01-09 2017-08-09 Sanofi Pasteur Biologics, LLC Purification of herpes virus
CA2873775C (en) 2012-05-21 2021-04-20 Sanofi Pasteur Limited Herpesvirus compositions and related methods
ES2959747T3 (es) 2013-02-15 2024-02-28 Bioverativ Therapeutics Inc Gen del factor VIII optimizado
WO2014145578A1 (en) * 2013-03-15 2014-09-18 The Children's Hospital Of Philadelphia Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture system
FR3010720B1 (fr) 2013-09-16 2017-08-11 Genethon Procede de production de virus enveloppes
FR3014901B1 (fr) 2013-12-17 2017-06-09 Genethon Procede de purification de virus ou vecteurs viraux enveloppes
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
CN104371982A (zh) * 2014-10-21 2015-02-25 武汉维诺赛生物技术有限公司 一种慢病毒的纯化方法
EP3215522B1 (en) 2014-11-03 2021-12-01 Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum T cell receptors directed against bob1 and uses thereof
EP3054007A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
CA3214521A1 (en) 2015-03-10 2016-09-15 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
PL3380620T3 (pl) 2015-11-23 2024-11-12 Novartis Ag Zoptymalizowane lentiwirusowe wektory transferowe i ich zastosowanie
EP3411478B1 (en) 2016-02-01 2022-06-08 Bioverativ Therapeutics Inc. Optimized factor viii genes
CN107043784A (zh) * 2016-02-05 2017-08-15 上海吉凯基因化学技术有限公司 一种慢病毒载体的制备方法
US20190225956A1 (en) 2016-05-10 2019-07-25 United States Government As Represented By The Department Of Veterans Affairs Lentiviral delivery of crispr/cas constructs that cleave genes essential for hiv-1 infection and replication
GB201614050D0 (en) 2016-08-17 2016-09-28 Glaxosmithkline Ip Dev Ltd Method for purifying viral vectors
EP3714055A1 (en) 2017-11-21 2020-09-30 CRISPR Therapeutics AG Materials and methods for treatment of autosomal dominant retinitis pigmentosa
CN111836892B (zh) 2017-12-21 2025-03-11 克里斯珀医疗股份公司 用于治疗2a型乌谢尔综合征的材料和方法
EP3728595A1 (en) 2017-12-21 2020-10-28 CRISPR Therapeutics AG Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
EP3502260A1 (en) 2017-12-22 2019-06-26 Oxford BioMedica (UK) Limited Retroviral vector
WO2019195727A1 (en) * 2018-04-05 2019-10-10 Oxford University Innovation Limited Compositions and methods for treating macular dystrophy
US11690907B2 (en) 2018-06-12 2023-07-04 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
US11529413B2 (en) 2018-06-12 2022-12-20 Kbio Holdings Limited Virus and antigen purification and conjugation
CN112566494B (zh) 2018-06-12 2023-05-23 Kbio控股有限公司 病毒和抗原纯化和偶联
US11696948B2 (en) 2018-06-12 2023-07-11 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
CA3109640A1 (en) * 2018-08-16 2020-02-20 Spacecraft Seven, Llc Production methods for viral vectors
KR20220034719A (ko) 2019-03-10 2022-03-18 시오 진 테라피스 인코포레이티드 파킨슨병을 치료하기 위한 유전자 요법 조성물 및 방법
WO2020214676A1 (en) * 2019-04-15 2020-10-22 Children's Hospital Medical Center Viral vector manufacturing methods
JP2022551219A (ja) 2019-08-23 2022-12-08 ロンザ ウォーカーズヴィル，インコーポレーテッド レンチウイルスベクターの製造方法および構築物
US12403164B2 (en) 2019-09-30 2025-09-02 Bioverativ Therapeutics Inc. Lentiviral vector formulations
KR20220097492A (ko) 2019-11-12 2022-07-07 옥스포드 바이오메디카(유케이) 리미티드 생산 시스템
KR20220139911A (ko) 2020-02-13 2022-10-17 옥스포드 바이오메디카(유케이) 리미티드 렌티바이러스 벡터의 생산
EP4118217A1 (en) 2020-03-13 2023-01-18 Oxford BioMedica (UK) Limited Lentiviral vectors
WO2021222222A1 (en) 2020-04-27 2021-11-04 Mccray Jr Paul B Compositions and methods for the treatment of cystic fibrosis
GB202007199D0 (en) 2020-05-15 2020-07-01 Oxford Biomedica Ltd Viral vector production
JP2023537565A (ja) 2020-06-24 2023-09-04 バイオベラティブ セラピューティクス インコーポレイテッド タンパク質を発現するように改変されたレンチウイルスベクターの調製物から遊離第ｖｉｉｉ因子を除去する方法
US20230304037A1 (en) * 2020-08-13 2023-09-28 Tmunity Therapeutics Inc. Methods for producing clinical-grade lentiviral vector
CN112226418B (zh) * 2020-09-25 2022-07-08 阜外华中心血管病医院 重组腺相关病毒纯化方法
WO2022071966A1 (en) * 2020-10-02 2022-04-07 Genelux Corporation Bioreactor production of virus from adherent cells
GB202017725D0 (en) 2020-11-10 2020-12-23 Oxford Biomedica Ltd Method
CN112899242A (zh) * 2021-02-03 2021-06-04 苏州博腾生物制药有限公司 慢病毒纯化工艺
GB202114530D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Retroviral vectors
GB202114528D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114532D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors
GB202114534D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Novel viral regulatory elements
GB202114529D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
EP4424705A1 (en) 2021-10-29 2024-09-04 Agc Inc. Composition for cell addition
EP4431600A1 (en) 2021-11-12 2024-09-18 Agc Inc. Virus purification method
GB202117844D0 (en) 2021-12-09 2022-01-26 Oxford Biomedica Ltd Purification method
GB202211935D0 (en) 2022-08-16 2022-09-28 Oxford Biomedica Ltd envelope proteins
CN116240241A (zh) * 2022-12-30 2023-06-09 上海本导基因技术有限公司 重组慢病毒载体的纯化制备方法
EP4658797A2 (en) * 2023-02-01 2025-12-10 Interius Biotherapeutics, Inc. Processes for the filtration or purification of viral particles
WO2024259299A1 (en) 2023-06-14 2024-12-19 The Broad Institute, Inc. Compositions and methods for identification of vhh antibodies that bind a target antigen

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78703A (en) 1985-05-10 1993-02-21 Benzon Alfred Method of producing extracellular enzymes, the enzymes produced thereby and compositions containing them; a hybrid plasmid and a dna fragment comprising dna encoding the enzymes; a microorganism harbouring the plasmid; and a method for removing nucleic acids from biological materials
DE4006630A1 (de) 1990-03-03 1991-09-12 Behringwerke Ag Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
US5512421A (en) 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
EP0572401B2 (en) 1991-02-19 2007-11-07 The Regents of the University of California Viral particles having altered host range
WO1995019427A1 (en) * 1994-01-12 1995-07-20 Genetic Therapy, Inc. Purification of retroviral vectors
WO1995025789A1 (en) 1994-03-22 1995-09-28 The Immune Response Corporation Highly efficient production and isolation of viral particles
US5681746A (en) * 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US5723315A (en) 1996-08-23 1998-03-03 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
EP0968182B1 (en) 1996-08-07 2004-05-06 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
CZ137399A3 (cs) 1996-10-17 1999-07-14 Oxford Biomedica (Uk) Limited Retrovirový produkční systém pro produkci replikačně defektivních vektorovýh partikulí
WO1998022588A2 (en) * 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
GB2351290A (en) 1998-05-22 2000-12-27 Oxford Biomedica Ltd Retroviral delivery sytem
GB9904905D0 (en) 1999-03-03 1999-04-28 Oxford Biomedica Ltd Cells
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
GB0024550D0 (enExample) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
WO2003084479A2 (en) * 2002-03-29 2003-10-16 Merck & Co., Inc. Large scale methods of producing adenovirus and adenovirus seed stocks
US7326555B2 (en) 2002-05-14 2008-02-05 Merck & Co., Inc. Methods of adenovirus purification
WO2004022761A1 (en) 2002-09-03 2004-03-18 Oxford Biomedica (Uk) Limited Retroviral vector and stable packaging cell lines
WO2004098531A2 (en) 2003-05-05 2004-11-18 Virxsys Corporation Increased transduction using abc transporter substrates and/or inhibitors
SE0302509D0 (sv) 2003-09-19 2003-09-19 Amersham Biosciences Ab Matrix for separation of polyethers and method of separation
KR20060095568A (ko) 2003-10-20 2006-08-31 엔에스진 에이/에스 파킨슨병의 생체내 유전자 요법
JP2007522814A (ja) * 2004-02-23 2007-08-16 クルセル ホランド ベー ヴェー ウイルスの精製方法
GB0526211D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
DK2007883T3 (da) * 2006-04-20 2012-02-06 Wyeth Llc Rensningsfremgangsmåder til isolering af renset vesikulær stomatitis-virus fra cellekultur
WO2008065430A2 (en) * 2006-12-01 2008-06-05 Oxford Biomedica (Uk) Limited Promoter construct
CA2678774A1 (en) 2007-03-01 2008-09-04 Advanced Vision Therapies, Inc. Treatment of diseases characterized by inflammation
EP2209814B1 (en) * 2007-11-13 2017-01-25 Bio-Technology General (Israel) Ltd. Dilute filtration sterilization process for viscoelastic biopolymers

Similar Documents

Publication Publication Date Title
JP2011524887A5 (enExample)
CN114456940B (zh) 一种提高大肠杆菌裂解过程中质粒稳定性的方法
CN104371982A (zh) 一种慢病毒的纯化方法
US10183984B2 (en) Method for extracting recombinant human serum albumin from transgenic rice grain
KR102364111B1 (ko) 세포 배양물로부터 폴리오바이러스의 정제 방법
CN101972479A (zh) 一种静注人免疫球蛋白的制备工艺
JP2023528657A (ja) 発酵ブロスの改善された脱塩及び例えばオリゴ糖のファインケミカルの精製
AU2019409513A1 (en) Method for separating biomass from a solution comprising biomass and at least one oligosaccaride
US20210277363A1 (en) Manufacture of Virus
CN108484422B (zh) 从酶转化液中提取β-丙氨酸的纯化结晶工艺及其系统
CN105669860B (zh) 一种抗手足口病人免疫球蛋白及其制备方法
CN116621948B (zh) 一种重组呼吸道合胞病毒f蛋白的纯化工艺方法
CN108368162A (zh) 一种重组人粒细胞刺激因子的复性及纯化方法
CN111662883A (zh) 一种制备及纯化溶瘤病毒的方法及重组溶瘤弹状病毒
US20220010286A1 (en) Process for producing a purified rhabdovirus from cell culture
CN111094309A (zh) 高纯度核黄素磷酸钠的制备方法
CN119799632A (zh) 一种功能增强的间充质干细胞外泌体的制备方法及其应用
CN112209999B (zh) 一种快速分离重组表皮生长因子发酵液中色素的方法
JP3989866B2 (ja) ヒアルロン酸又は／及びキチンの分離・精製方法
CN118389625A (zh) 一种从果糖溶液中联产氨基葡萄糖盐酸盐和d-阿洛酮糖的方法
WO2025157970A1 (en) Large scale methods for producing plasmid dna
CN117660373A (zh) 一种慢病毒大规模纯化方法及其应用
EA049917B1 (ru) Способ получения очищенного рабдовируса из клеточной культуры
CN106046127A (zh) 一种白喉类毒素的制备方法
UA52744U (uk) Спосіб одержання антигену для діагностики лейкозу великої рогатої худоби в реакції імунодифузії (рід)